Canaccord raised the firm’s price target on Delcath Systems to $18 from $14 and keeps a Buy rating on the shares. The firm noted they announced approval of Hepzato, a drug/device combination that delivers high doses of melphalan to the liver for the treatment of unresectable metastatic uveal melanoma (mUM, aka metastatic ocular melanoma, mOM) with metastases to the liver. The label appears clean, and includes both treatment-naive and previously treated patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DCTH:
- Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy
- Delcath Systems announces FDA approval of Hepzato KIT
- Delcath Systems announces FDA approval of HEPZATO KIT in mUM
- Delcath Systems reports Q2 EPS (58c), consensus (60c)
- Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update